Navigation Links
HIV Drug in Microbicide Gel Safe for Daily Use

None of the 200 women volunteers got HIV during 6-month study

TUESDAY, Feb. 26 (HealthDay News) -- A vaginal microbicide gel that contains the antiretroviral drug tenofovir is safe for HIV-negative women to use every day, according to a six-month study of 200 women in India and the United States.

This study, by researchers at the U.S. National Institutes of Health-funded Microbicide Trials Network, looked at whether women were able to adhere to a regimen of either daily or sex-dependent use of the gel. Both regimens proved equally safe, and women's adherence to each regimen was similar. Notably, none of the women who used the new gel got HIV during the study period.

There were no differences in liver, blood and kidney function between women who used the gel and those who used a placebo, nor were there any differences in rates of genital symptoms such as itching and burning.

The compliance rate was 83 percent among women in the daily use group, and 80 percent among women instructed to use the gel within two hours of having sex.

The results are an advance in efforts to use microbicides to prevent HIV infection in women, the researchers said. Worldwide, almost half of people with HIV/AIDS are women, and 70 percent to 90 percent of all HIV infections in women are due to heterosexual intercourse. In many areas of the world, even married women and those with steady partners are at risk for HIV infection.

Correct and consistent use of male condoms prevents HIV infection, but it's often difficult for some women to convince men to use condoms.

"Finding that daily use is both safe and feasible is important, because we believe a daily approach may provide more sustainable protection against the virus in women who can't always predict when they will have sex," study leader Sharon L. Hillier, said in a prepared statement.

"Based on what we have learned, we can proceed with greater confidence on a path that will answer whether tenofovir gel and other gels with HIV-specific compounds will be able to prevent sexual transmission of HIV in women when other approaches have failed to do so. It is a critical time for all of us engaged in HIV prevention, and I truly believe we are turning a corner," said Hillier, director of reproductive sciences at the University of Pittsburgh School of Medicine.

Microbicides designed to prevent HIV infection are applied on the inside of the vagina or rectum.

The study was presented this week at Microbicides 2008, an international meeting in New Delhi, India.

More information

The U.S. Centers for Disease Control and Prevention has more about HIV/AIDS and women.

-- Robert Preidt

SOURCE: Microbicide Trials Network, news release, Feb. 25, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
2. Trial finds tenofovir gel safe for daily use and most women adhered to study regimens
3. Daily Stress May Raise Womens Risk of Cervical Cancer
4. New Renuva Daily Balance Spray Is Designed to Be the Easiest and Best Way to Take Daily Vitamins and Minerals
5. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
6. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
7. Research shows a daily does of beetroot juice can beat high blood pressure
8. FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
9. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
10. Los Angeles Daily Journal Names Richardson & Patel Verdict Top in the State of California for 2007
11. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
Post Your Comments:
Related Image:
HIV Drug in Microbicide Gel Safe for Daily Use
(Date:11/27/2015)... ... , ... According to an article published November 6th by The ... of British Columbia suggested that laws requiring bicyclists to wear helmets may not actually ... the reason for the controversial conclusion is that, while helmets have certainly prevented a ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... toilets were," said an inventor from Hillside, N.J. "Many people catch diseases simply ... so that individuals will always be protected from germs." , He developed the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
Breaking Medicine Technology: